Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1524 of 5804
-
Brief therapy aims to stop PTSD before it starts in spinal cord injury patients
Symptom relief ENROLLING_BY_INVITATIONThis study will examine the use brief prolonged exposure (Brief PE) therapy compared to standard clinical care to reduce posttraumatic distress among people who have had a spinal cord injury and are receiving rehabilitation in an inpatient setting.
Phase: NA • Sponsor: Baylor Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Could a nasal spray help Parkinson's? new trial tests insulin and glutathione combo
Disease control Recruiting nowThis study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.
Phase: PHASE2 • Sponsor: Gateway Institute for Brain Research • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Heart attack patients: can a common gout pill improve bypass recovery?
Disease control CompletedThe present study seeks to evaluate the effectiveness of the use of perioperative colchicine with regard to operative complications, in patients with acute coronary syndrome and indication for cardiac post-surgical revascularization. Patients will be selected and randomized whil…
Phase: PHASE2 • Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a Smartphone-Guided exercise program ease the burden of atrial fibrillation?
Disease control CompletedAtrial fibrillation (AF) patients suffer a high symptom burden and reduced quality of life (QoL), high hospitalization rates and few effective treatment options. They have a high burden of cardiovascular risk factors and events. Lifestyle changes and exercise is a cornerstone of …
Phase: NA • Sponsor: Norwegian University of Science and Technology • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Heart attack drug targets tiny vessels, not blockages
Disease control Recruiting nowPatients with heart attack or heart injury are tested (angiogram) for blockages in their arteries. Patients may develop heart problems caused by damage to small (microvascular) blood vessels. Eplerenone, a mineralocorticoid receptor-selective antagonist, reduces blood vessel inju…
Phase: PHASE2 • Sponsor: NHS National Waiting Times Centre Board • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug targets Alzheimer's proteins in Early-Onset patients
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum trea…
Phase: PHASE1 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Virtual reality could make head and neck cancer surgery more precise
Knowledge-focused Recruiting nowThis clinical trial studies the use of virtual reality technology and three dimensional surgery (3D-surgery) modeling to enhance current treatments in head and neck cancer surgery. Virtual reality 3D-surgery modeling may improve quality of surgical planning and interdisciplinary …
Phase: NA • Sponsor: Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Promising combo tackles rare sarcoma in early trial
Disease control OngoingThis research study involves the study drug lurbinectedin in combination with doxorubicin. This research has two parts. The first part is being done to determine the tolerability of lurbinectedin with doxorubicin in people with soft tissue sarcoma. The second part is a randomize…
Phase: PHASE1, PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a gene test pick the right blood pressure pill for black patients?
Disease control OngoingLysine specific demethylase-1 (LSD1) is an epigenetic regulator of gene transcription involved in the pathophysiology of elevated blood pressure and likely renal damage in Blacks. This project investigates whether a genetically driven anti-hypertensive approach proves superior in…
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New psoriasis pill shows promise in Mid-Stage trial
Disease control CompletedTh purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New inhaler aims to stop prolonged seizures fast and safely
Symptom relief ENROLLING_BY_INVITATIONThe purpose of the study is to evaluate the long-term safety and tolerability of Staccato alprazolam.
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Blood thinner breakthrough could stop clots in rare anemia
Prevention Recruiting nowAutoimmune hemolytic anemia (AIHA) is a rare autoimmune disease (incidence \<1/100,000 population) responsible for the destruction of red blood cells by the host immune system, notably through the action of autoantibodies. Apart from complications related to anemia, the occurren…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Prevention
Last updated Jun 27, 2026 08:06 UTC
-
New drug trial hopes to shrink Hard-to-Treat tumors
Disease control OngoingThis first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
Phase: PHASE1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Stem cell shots take on long COVID: hope for millions?
Symptom relief CompletedThis study will enroll up to 80 subjects with Chronic Post COVID-19 Syndrome. Subjects will receive four intravenous injections of either allogeneic HB-adMSC's or a placebo over 10 weeks with two follow-up visits and an end of study visit at week 26.
Phase: PHASE2 • Sponsor: Hope Biosciences Research Foundation • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Cancer pill may boost ablation success in aggressive liver tumors
Disease control OngoingPercutaneous ablation (PA) is the only non-surgical curative treatment of hepatocellular carcinoma (HCC). Due to its excellent tolerance, particularly in patients with portal hypertension or bearing comorbidities, it now represents in France nearly 70% of the first-line curative …
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New shot could help raise platelet levels in chronic blood disorder
Disease control Recruiting nowThis is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail takes on hard-to-treat lymphomas
Disease control OngoingThis is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the cl…
Phase: PHASE1 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for rare dementia: experimental drug DNL593 enters human trials
Disease control OngoingThis is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) perio…
Phase: PHASE1, PHASE2 • Sponsor: Denali Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Could a flu drug help stroke patients recover?
Disease control Recruiting nowThe investigators aim to examine whether amantadine can help patients recover from stroke. This will be a blinded randomized clinical trial (RCT). Patients will be randomized post-ischemic or hemorrhagic stroke either to the placebo arm or amantadine arm. Patients will be on stud…
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New online 'Behavioral Vaccine' aims to stop teen depression before it starts
Prevention OngoingPrevention of depressive disorders has become a key priority for the NIMH, but the investigators have no widely available public health strategy to reduce morbidity and mortality. To address this need, the investigators developed and evaluated the primary care based-technology "b…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC